Skinny Labels and the Line Between Mere Information and Inducement to Infringe in ANDA Litigation

May 08, 2018

A drug whose original patent protection for any and all uses (i.e., composition of matter protection) has expired often remains protected years afterwards by patent(s) covering later-discovered uses such as methods of dosing, administering, or manufacturing the drug, or methods of treating particular indications or subsets of patients. 

In this article, Joseph Arico, Andrea Reid and Carl Morales talk about the practice of generic drug manufacturers obtaining FDA approval to market generic drugs with uses that are not covered by patents, also known as "skinny labelling."

Read the full article »